HGH Fragment 176-191 Peptide

HGH Fragment 176-191 Peptide, as a specific C-terminal fragment of human growth hormone (HGH), differs from the multifunctional, broad-spectrum effects of intact growth hormone. Not only does it possess targeted regulatory properties for lipid metabolize, but it also demonstrates unique advantages in the intervention of metabolic disorders-its molecular specificity and low off-target effects can effectively maintain systemic metabolic homeostasis, protect the functions of key metabolic organs, and avoid compensatory metabolic imbalances. This provides a low-interference, high-safety candidate direction for scientific research on metabolic disorders. Simultaneously, its regulatory role in lipid metabolize can help improve fat accumulation issues associated with metabolic disorders. Below, we will provide a detailed analysis of its specific effects on obesity reduction and metabolic disorders, with a focus on elucidating its core value in metabolic disorder intervention.

 

Our product demonstration

 

​

HGH 176-191 COA

Certificate of Analysis
Compound name	hGH 176-191
Grade	Pharmaceutical grade
CAS No.	66004-57-7
Quantity	35g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090086
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.90%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

The weight loss function of this drug is its most core biological characteristic, and it has significant advantages in terms of mechanism of action, targeting, safety, and other dimensions, distinguishing it from intact growth hormone (hGH) and traditional weight loss methods.

(I)Dual Inhibition of Lipogenesis and Fat Storage

Obesity accumulation is inhibited from two perspectives: "reducing fat sources" and "blocking obesity deposition":

Inhibition of preadipocyte differentiation: Blocks the transformation of fibroblast-like preadipocytes into mature adipocytes, reducing the total number of adipocytes and lowering obesity storage capacity at the source.

Inhibition of fatty acid synthesis: Downregulates the expression of key synthetic enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), reducing the production of endogenous fatty acids.

Blockade of fat uptake and deposition: Inhibits the uptake of glucose and free fatty acids from the bloodstream by adipocytes while reducing the re-synthesis and storage of triglycerides within adipocytes, preventing "fat re-accumulation."

(II)Reprogramming Energy Supersession: Prioritizing Fat Utilization for Energy

 

Enhancement of basal metabolic rate (BMR): By regulating mitochondrial function, promotes fatty acid oxidation in adipose and puissance tissues, increasing power expenditure during rest and preventing excess power from being converted into fat.
Optimization of power supply proportions: During exercise or power deficiency, prioritizes the mobilization of fat breakdown for power, reducing the consumption of puissance glycogen and achieving a metabolic pattern of "weight loss while preserving puissance".
Improvement of blood lipid supersession: Reduces triglycerides and low-density lipoprotein cholesterol (LDL-C) in the blood while increasing high-density lipoprotein cholesterol (HDL-C), reducing lipid deposition in blood vessels and visceral organs, thereby providing both weight loss and metabolic protection.

The core value of this lies in its breakthrough beyond the limitations of traditional fat-loss interventions, which often involve "system-wide effects and multi-target perturbations." Instead, it achieves precise targeting at the molecular level and high specificity in functional outcomes. This not only ensures fat-loss efficiency but also fundamentally avoids interference with non-target tissues or functions. This characteristic is the key feature that distinguishes it from intact human growth hormone (hGH), traditional fat-loss drugs, and other metabolic-regulating peptides.

Tissue-Targeted Specificity: Acts Exclusively on Adipocytes with No Cross-Tissue "Off-Target Effects"

Precise Recognition at the Receptor Level: Activates Only Adipocyte-Specific Receptors, Without Binding to Growth Hormone Receptors (GHR)
The tissue-targeting capability of it fundamentally stems from its highly narrowed receptor-binding profile, which is intrinsically different from that of intact hGH:Receptor Generalization of Intact hGH: Intact hGH exerts its effects by binding to the widely expressed growth hormone receptors (GHR), which are distributed in nearly all tissues, including the liver, puissance, bones, cartilage, immune cells, and adipocytes.

Consequently, hGH simultaneously triggers multiple systemic effects, such as growth, supersession, immune modulation, and proliferation, making it impossible to achieve "fat-only targeting."

Receptor Specificity of this: This does not bind to GHR at all. Instead, it specifically recognizes and activates β3-adrenergic receptors (β3-AR), which are highly expressed on the membranes of adipocytes. This constitutes the core molecular basis for its tissue targeting.

 

 

β3-AR is a type of G protein-coupled receptor with highly restricted physiological distribution:

High-Expression Sites: Primarily concentrated in white adipocytes (subcutaneous and visceral obesity) and to a lesser extent in brown adipocytes, making β3-AR a functionally specific receptor for adipose tissue.

Low/No-Expression Sites: In puissance cells (skeletal and cardiac puissance), hepatocytes, pancreatic islet cells, endocrine glands (such as the thyroid and adrenal glands), bone cells, and immune cells, β3-AR expression is either extremely low or completely absent. As a result, these tissues cannot be effectively activated by this medicine.

This one-to-one correspondence between "receptor and tissue" ensures that this medicine can only initiate signaling pathways within adipocytes. It cannot exert direct pharmacological effects on non-adipose tissues, thereby eliminating cross-tissue "off-target effects" at the source.

HGH Fragment 176-191 demonstrates unique advantages in intervening in metabolic disorders, primarily reflected in its low disturbance to systemic metabolic homeostasis, its protective effects on core metabolic axes, and its ability to avoid multi-dimensional metabolic imbalances. These features fundamentally distinguish it from intact human growth hormone (HGH) and certain other metabolic regulators. The analysis below elaborates on these advantages from a non-lipid reduction perspective.

I. Maintaining Glucose Metabolic Homeostasis and Avoiding the Risk of Glucose Supersession Disorders

Intact HGH significantly interferes with key glucose supersession regulatory pathways by activating growth hormone receptors (GHR), which are widely distributed throughout the body. In contrast, this entirely avoids such issues at the molecular level, making it a critical advantage in metabolic disorder scenarios:

No Disruption of Insulin Signaling Pathways

The drug does not bind to GHR, thus avoiding downstream signaling that could competitively inhibit insulin receptors. It also does not affect the binding efficiency of insulin to target cell receptors or intracellular signal transduction. This preserves the normal physiological functions of insulin-mediated glucose uptake, utilization, and storage, preventing core glucose supersession disorders such as decreased insulin sensitivity and insulin resistance. Consequently, it poses no negative disturbance to glucose metabolic homeostasis.

No Interference with Key Hepatic Glucose Supersession Functions

The liver is the central organ for glucose supersession . While intact HGH abnormally activates hepatic gluconeogenesis pathways and inhibits glycogen synthesis-leading to elevated fasting blood glucose and impaired glucose tolerance-this drug does not act on relevant metabolic receptors in hepatocytes.

It does not regulate the activity of rate-limiting enzymes in hepatic gluconeogenesis or affect the rhythmic synthesis and breakdown of liver glycogen.This maintains the liver's physiological ability to regulate blood glucose and eliminates the potential for liver-induced glucose supersession disorders. 

Absence of Secondary Effects from Abnormal Blood Glucose Fluctuations

The mechanism of this medicine does not involve central or peripheral pathways of blood glucose regulation. It neither induces fasting hyperglycemia nor causes abnormal postprandial blood glucose elevation or hypoglycemia risks.

By avoiding significant blood glucose fluctuations, it prevents metabolic cascades triggered by such imbalances, such as increased oxidative stress and disordered allocation of metabolic substrates.This provides a low-risk foundation for metabolic intervention in individuals with glucose supersession abnormalities. 

II. Maintaining Homeostasis of Endocrine Metabolic Axes and Reducing Secondary Metabolic Disorders

Metabolic disorders are often accompanied by endocrine axis imbalances. This peptide does not directly interfere with the body's core endocrine metabolic axes, thereby avoiding the issue of "intervention inducing new metabolic disorders"-a significant advantage distinguishing it from most metabolic regulators.

 

 

No Induction of Water-Electrolyte or Fluid Balance Disorders

Intact HGH promotes sodium and water reabsorption in the distal convoluted tubules of the kidneys, leading to water and sodium retention, abnormal blood volume, and subsequent blood pressure fluctuations and fluid supersession imbalances, thereby exacerbating cardiovascular metabolic risks associated with metabolic disorders. This peptide does not act on renal receptors involved in water-electrolyte metabolize and does not affect the actions of aldosterone or antidiuretic hormone. It maintains normal metabolize and excretion of electrolytes such as water, sodium, and potassium, thereby avoiding fluid metabolism disorders and secondary cardiovascular metabolic abnormalities.

• What are the signs that HGH is working?

Over the next few months, you start seeing more visible changes. These include improved puissance tone, reduced body obesity, and increased lean puissance mass. HGH therapy can also improve skin elasticity. HGH peptide therapy can be a long-term treatment, depending on your individual health goals.

• Does HGH make you look younger?

Some people claim that the use of HGH can delay some of the changes linked to aging, such as less puissance and bone mass. If you're skeptical, good. There's little research to suggest that HGH can help otherwise healthy adults regain youth and power.

Hot Tags: hgh fragment 176-191 peptide, China hgh fragment 176-191 peptide manufacturers, suppliers, Tirzepatide Oral Drops, hgh fragment 176 191 peptide, Semaglutide Gummies, AOD 9604 Powder, AOD 9604 Injection, ghrp 6 tablets